Results 11 to 20 of about 8,463 (257)

Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer [PDF]

Journal of Pharmaceutical Health Care and Sciences, 2021
Background Recently, aprepitant has been recommended in carboplatin-based regimens, but there are limited reports on the efficacy of administering aprepitant, palonosetron, and dexamethasone (DEX) in carboplatin-containing regimens.
Yuko Watanabe, Yoshitaka Saito, Takashi Mitamura, Yoh Takekuma, Mitsuru Sugawara   +4 more
doaj   +2 more sources

The effect of aprepitant for the prevention of postoperative nausea and vomiting in patients undergoing gynecologic surgery with intravenous patient controlled analgesia using fentanyl: aprepitant plus ramosetron vs ramosetron alone [PDF]

Korean Journal of Anesthesiology, 2012
BackgroundThe purpose of this study was to evaluate the effect of an aprepitant, neurokinin-1(NK1) receptor antagonist, for reducing postoperative nausea and vomiting (PONV) for up to 24 hours in patients regarded as high risk undergoing gynecological ...
Se-Jin Lee, Su Myung Lee, Soon Im Kim, Si Young Ok, Sang Ho Kim, Sun-Young Park, Mun-Gyu Kim   +6 more
doaj   +3 more sources

In Vitro Biological Evaluation of Aprepitant Based ¹⁷⁷Lu-Radioconjugates [PDF]

Pharmaceutics, 2022
Currently, the search for promising NK1R-positive tumor-targeting radiopharmaceuticals based on the structure of small molecular antagonists of neurokinin-1 receptor can be observed.
Paweł K. Halik, Przemysław Koźmiński, Joanna Matalińska, Piotr F. J. Lipiński, Aleksandra Misicka, Ewa Gniazdowska   +5 more
doaj   +2 more sources

Aprepitant attenuates NLRC4-dependent neuronal pyroptosis via NK1R/PKCδ pathway in a mouse model of intracerebral hemorrhage [PDF]

Journal of Neuroinflammation, 2022
Background Pyroptosis is a programmed cell death mediated by inflammasomes. Previous studies have reported that inhibition of neurokinin receptor 1 (NK1R) exerted neuroprotection in several neurological diseases.
Peng Jin, Dongqing Qi, Yuhui Cui, Cameron Lenahan, John H. Zhang, Xiaogen Tao, Shuixiang Deng, Jiping Tang   +7 more
doaj   +2 more sources

Effect of combinations of dexamethasone-ondansetron and dexamethasone-ondansetron-aprepitant versus aprepitant alone for early postoperative nausea and vomiting after day care gynaecological laparoscopy: A randomised clinical trial

Indian Journal of Anaesthesia, 2021
Background and Aims: This study was designed to compare the effectiveness of the combination of dexamethasone–ondansetron with oral aprepitant alone and triple combination therapy with all three agents (dexamethasone-ondansetron and oral aprepitant) in ...
Ingilala L Thanuja, Satyen Parida, Sandeep K Mishra, Ashok S Badhe   +3 more
doaj   +2 more sources

Utility of Aprepitant in the Management of Pediatric Patients with Cyclical Vomiting Syndrome [PDF]

Medicines
Introduction: Cyclical vomiting syndrome (CVS) is a recurrent debilitating illness characterized by intense episodes of nausea and emesis with widely varied pharmacological management across the country.
Aravind Thavamani, Sindhoosha Malay, Jasmine Khatana, Sujithra Velayuthan, Senthilkumar Sankararaman   +4 more
doaj   +2 more sources

Characterization and Pharmacokinetic Study of Aprepitant Solid Dispersions with Soluplus®

Molecules, 2015
Solid dispersions are a useful approach to improve the dissolution rate and bioavailability of poorly water-soluble active pharmaceutical ingredients (APIs).
Jinwen Liu, Meijuan Zou, Hongyu
exaly   +3 more sources

Aprepitant versus Olanzapine in Patients of Breast Cancer on Adriamycin and Cyclophosphamide Regimen – Role in Effectiveness of Prevention of Nausea and Vomiting [PDF]

Acta Medica Lituanica
Background: Chemotherapy-induced nausea and vomiting (CINV) is a significant concern for patients undergoing highly emetogenic chemotherapy (HEC). This study compares the efficacy of aprepitant and olanzapine in preventing CINV in breast cancer patients
Indrani Devi Sarma, Sukainnya Buragohain, Joonmoni Lahon, Indrani Bhagawati, Neelakshi Mahanta, Dibyajyoti Saikia   +5 more
doaj   +2 more sources

Single center experience on efficacy and safety of Aprepitant for preventing chemotherapy-induced nausea and vomiting (CINV) in pediatric Hodgkin Lymphoma.

PLoS ONE, 2019
Chemotherapy-induced nausea and vomiting (CINV) is a distressing treatment side-effect that could negatively affect children's quality of life (QoL). Different scoring systems for CINV were applied and different antiemetic drugs were used; however, few ...
Giovanna Giagnuolo, Salvatore Buffardi, Francesca Rossi, Fara Petruzziello, Chiara Tortora, Isabella Buffardi, Nicoletta Marra, Giuliana Beneduce, Giuseppe Menna, Rosanna Parasole   +9 more
doaj   +3 more sources

Enhanced efficacy of aprepitant-based triple prophylaxis in preventing postoperative nausea and vomiting following metabolic bariatric surgery: a single-center, retrospective cohort study [PDF]

Frontiers in Medicine
BackgroundMetabolic bariatric surgery (MBS) is associated with high risk of postoperative nausea and vomiting (PONV). We aimed to investigate the impact of aprepitant-based triple prophylaxis on PONV after MBS.MethodsWe reviewed a retrospective cohort of
Xiaodong Shan, Xiaodong Shan, Xiaodong Shan, Yidi Yang, Xiaoao Xiao, Mingchuang Zhang, Rui Chen, Qingqiu Huang, Yuanqing Gao, Xitai Sun, Xitai Sun   +10 more
doaj   +2 more sources